Rhythm Pharmaceuticals announces promising results from their Phase 3 TRANSCEND trial, where setmelanotide significantly reduced BMI in patients with acquired hypothalamic obesity. This breakthrough offers new hope for treating this rare condition resulting from hypothalamic damage.